The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

A drug used to help Canadians lose weight has now been approved to reduce the risk of non-fatal heart attacks. Novo Nordisk ...

Health Canada has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes.